4-Substituted 1,5-diarylpyrazole, analogues of celecoxib: Synthesis and preliminary evaluation of biological properties

Farmaco

Volumn 58, Issue 9, 2003, Pages 795-808

  Menozzi, Giulia ^a   Merello, Luisa ^a   Fossa, Paola ^a   Mosti, Luisa ^a   Piana, Antonietta ^a   Mattioli, Francesca ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Analgesic agents; Anti inflammatory agents; COX inhibitors; Pyrazole derivatives

Indexed keywords

ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; BENZENESULFONAMIDE DERIVATIVE; CARBOXYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIPYRONE; INDOMETACIN; MORPHINE; PYRAZOLE DERIVATIVE; SODIUM;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING SITE; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVE SITE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0141676118     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(03)00136-8     Document Type: Article

References (34)

1. Talley J.J. Selective inhibitors of cyclooxygenase-2 (COX-2). King F.D., Oxford A.W. Progress in Medicinal Chemistry. 36:1999;201-234 Elsevier, Amsterdam. and references cited therein.
2. Howe L.R., Dannenberg A.J. A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer. Semin. Oncol. 29:2002;111-119.
3. Slater D., Dennes W., Sawdy R., Allport V., Bennet P. Expression of cyclo-oxygenase types-1 and -2 in human fetal membranes throughout pregnancy. J. Mol. Endocrinol. 22:1999;125-130.
4. Aisen P.S. Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease. J. Pain Symptom Manage. 23:2002;S35-40.
5. Guo J.S., Cho C.H., Lam-Liu E.S., Choy H.T., Wang J.Y., Leung-Koo M.W. Antiangiogenic effect of a highly selective cyclooxygenase-2 inhibitor on gastric ulcer healing in rats. Toxicol. Appl. Pharmacol. 183:2002;41-45.
6. Dannhardt G., Kiefer W., Krämer G., Maehrlein S., Nowe U., Fiebich B. The pyrrole moiety as a template for COX-1/COX-2 inhibitors. Eur. J. Med. Chem. 35:2000;499-510.
7. Hinz B., Brune K. Specific COX-2 inhibitors. Basis and options of a pharmacotherapeutical concept. Anaesthesist. 49:2000;964-971.
8. Hashimoto H., Imamura K., Haruta J., Wakitani K. 4-(4-Cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522. J. Med. Chem. 45:2002;1511-1517.
9. McMurray R.W., Hardy K.J. Cox-2 inhibitors: today and tomorrow. Am. J. Med. Sci. 323:2002;181-189.
10. Penning T.D., Talley J.J., Bertenshaw S.R., Carter J.S., Collins P.W., Docter S., Graneto M.J., Lee L.F., Malecha J.W., Miyashiro J.M., Rogers R.S., Rogier D.J., Yu S.S., Anderson G.D., Burton E.G., Cogburn J.N., Gregory S.A., Koboldt C.M., Perkins W.E., Seibert K., Veenhuizen A.W., Zhang Y.Y., Isakson P.C. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem. 40:1997;1347-1365.
11. Prasit P., Wang Z., Brideau C., Chan C.C., Charleson S., Cromlish W., Ethier D., Evans J.F., Ford-Hutchinson A.W., Gauthier J.Y., Gordon R., Guay J., Gresser M., Kargman S., Kennedy B., Leblanc Y., Léger S., Mancini J., O'Neill G.P., Ouellet M., Percival M.D., Perrier H., Riendeau D., Rodger I., Tagari P., Thérien M., Vickers P., Wong E., Xu L.J., Young R.N., Zamboni R. The discovery of rofecoxib, [MK 966, Vioxx®, 4-(4′ -methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor. Biorg. Med. Chem. Lett. 9:1999;1773-1778.
12. Menozzi G., Mosti L., Merello L., Piana A., Armani U., Ghia M., Angiola M., Mattioli F. 4-Dialkylamino-1-(5-substituted or unsubstituted 1-phenyl-1H-pyrazol-4-yl)butan-1-ols: synthesis and evaluation of analgesic, anti-inflammatory and platelet anti-aggregating activities. Farmaco. 55:2000;219-226.
13. Reitz D.B., Li J.J., Norton M.B., Reinhard E.J., Collins J.T., Anderson G.D., Gregory S.A., Koboldt C.M., Perkins W.E., Seibert K., Isakson P.C. Selective cyclooxygenase inhibitors: novel 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors. J. Med. Chem. 37:1994;3878-3881.
14. Khanna I.K., Weiner R.M., Yu Y., Xu X.D., Koszyk F.J., Collins P.W., Koboldt C.M., Veenhuizen A.W., Perkins W.E., Casler J.J., Masferrer J.L., Zhang Y.Y., Gregory S.A., Seibert K., Isakson P.C. 1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents. J. Med. Chem. 40:1997;1634-1647.
15. Liu H., Huang X., Shen J., Luo X., Li M., Xiong B., Chen G., Shen J., Yang Y., Jiang H., Chen K. Inhibitory mode of 1,5-diarylpyrazole derivatives against cyclooxygenase-2 and cyclooxygenase-1: molecular docking and 3D QSAR analyses. J. Med. Chem. 45:2002;4816-4827.
16. Kalgutkar A.S., Marnett A.B., Crews B.C., Remmel R.P., Marnett L.J. Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. J. Med. Chem. 43:2000;2860-2870.
17. Kurumbail R.G., Stevens A.M., Gierse J.K., McDonald J.J., Stegeman R.A., Pak J.Y., Gildehaus D., Miyashiro J.M., Pennig T.D., Seibert K., Isakson P.C., Stallings W.C. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 384:1996;644-648.
18. Talley J.J., Brown D.L., Carter J.S., Graneto M.J., Koboldt C.M., Masferrer J.L., Perkins W.E., Rogers R.S., Shaffer A.F., Zhang Y.Y., Zweifel B.S., Seibert K. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, Valdecoxib: a potent and selective inhibitor of COX-2. J. Med. Chem. 43:2000;775-777.
19. Menozzi G., Mosti L., Schenone P. Reaction of 2-dimethylaminomethylene-1,3-diones with dinucleophiles. VI. Synthesis of ethyl or methyl 1,5-disubstituted 1H-pyrazole-4-carboxylates. J. Heterocyclic Chem. 24:1987;1669-1675.
20. Menozzi G., Schenone P., Mosti L., Mattioli F. Synthesis of 5-substituted 1-aryl-1H-pyrazole-4-acetonitriles, 4-methyl-1-phenyl-1H-pyrazole-3-carbonitriles and pharmacologically active 1-aryl-1H-pyrazole-4-acetic acids. J. Heterocyclic Chem. 30:1993;997-1002.
21. Menozzi G., Mosti L., Fossa P., Mattioli F., Ghia M. ω -Dialkylaminoalkyl ethers of phenyl(5-substituted 1-phenyl-1H-pyrazol-4-yl)methanols with analgesic and anti-inflammatory activity. J. Heterocyclic Chem. 34:1997;963-968.
22. Morimura S. Formation of 3,5-dicyano-4-(N,N-dimethylformamidino)-2,6-diphenyl-4H-pyran from ω-cyanoacetophenone. Heterocycles. 14:1980;1449-1454.
23. Breaux E.J., Zwikelmaier K.E. An improved general synthesis of 4-aryl-5-pyrimidinecarboxylates. J. Heterocyclic Chem. 18:1981;183-184.
24. H.W. Gschwend, Pyrazolobenzazepines, US 4 028 381 (1977); Chem. Abstr. 87 (1977) 117854u.
25. J.E. Franz, D.E. Schafer, L.H. Brannigan, Herbicidal compositions containing 5-aryl-4-isoxazolecarboxylate, Belg. 880 849 (1980); Chem. Abstr. 94 (1981) 78442f.
26. R. Pepin, C. Schmitz, G.B. Lacroix, P. Dellis, C. Veyrat, (Morpholinocarbonyl)benzothiophenes and analogs as agrochemical fungicides and their preparation, Eur. Pat. Appl. EP 360 701 (1990); Chem. Abstr. 113 (1990) 78409m.
27. Kuno A., Sugiyama Y., Katsuta K., Sakai H., Takasugi H. Studies on cerebral protective agents. II. Novel 4-arylpyrimidine derivatives with anti-anoxic and anti-lipid peroxidation activities. Chem. Pharm. Bull. 40:1992;2423-2431.
28. Winter C.A., Risley E.A., Nuss G.W. Anti-inflammatory and antipyretic activities of indomethacin, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-indole-3-acetic acid. J. Pharmacol. Exp. Ther. 141:1963;369-376.
29. Koster R., Anderson M., De Beer E.J. Synthetic analgesics. Dithienbutenyl dithienbuthylamines. Fed. Proc. 18:1959;412-421.
30. Born G.V.R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 194:1962;927-929.
31. Picot D., Loll P.J., Garavito R.M. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature. 367:1994;243-249.
32. Mohamadi F., Richards N.G.J., Guida W.C., Liskamp R., Lipton M., Caufield C., Chang G., Hendrickson T., Still W.C. MacroModel - an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 11:1990;440-467.
33. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19:1998;1639-1662.
34. Vane J.R., Bakhle Y.S., Botting R.M. Cyclooxygenase 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38:1998;97-120.